Intracranial Hemorrhage in Patients with Anticoagulant Therapy Undergoing Stereotactic Radiosurgery for Brain Metastases: A Bi-Institutional Analysis.
CyberKnife
anticoagulant therapy
anticoagulation
brain metastases
intracranial hemorrhage
intratumoral hemorrhage
stereotactic radiosurgery
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 Jan 2022
18 Jan 2022
Historique:
received:
22
11
2021
revised:
09
01
2022
accepted:
12
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
Stereotactic radiosurgery (SRS) is a well-established treatment modality for brain metastases (BM). Given the manifold implications of metastatic cancer on the body, affected patients have an increased risk of comorbidities, such as atrial fibrillation (AF) and venous thromboembolism (VTE), which includes pulmonary embolism (PE) and deep-vein thrombosis (DVT). These may require therapeutic anticoagulant therapy (ACT). Limited data are available on the risk of intracranial hemorrhage (ICH) after SRS for patients with BM who are receiving ACT. This bi-institutional analysis aimed to describe the bleeding risk for this patient subgroup. Patients with ACT at the time of single-fraction SRS for BM from two institutions were eligible for analysis. The cumulative incidence of ICH with death as a competing event was assessed during follow-up with magnetic resonance imaging or computed tomography. Forty-one patients with 97 BM were included in the analyses. The median follow-up was 8.2 months (range: 1.7-77.5 months). The median and mean BM volumes were 0.47 and 1.19 cubic centimeters, respectively. The most common reasons for ACT were PE (41%), AF (34%), and DVT (7%). The ACT was mostly performed utilizing phenprocoumon (37%), novel oral anticoagulants (32%), or low-molecular-weight heparin (20%). Nine BM from a group of five patients with ICH after SRS were identified: none of them caused neurological or any other deficits. The 6-, 12-, and 18-month cumulative bleeding incidences per metastasis were 2.1%, 12.4%, and 12.4%, respectively. The metastases with previous bleeding events and those originating from malignant melanomas were found to more frequently demonstrate ICH after SRS ( Patients receiving an ACT and single-fraction SRS for small- to medium-sized BM did not seem to have a clinically relevant risk of ICH. Previous bleeding and metastases originating from a malignant melanoma may favor bleeding events after SRS. Further studies are needed to validate our reported findings.
Sections du résumé
BACKGROUND
BACKGROUND
Stereotactic radiosurgery (SRS) is a well-established treatment modality for brain metastases (BM). Given the manifold implications of metastatic cancer on the body, affected patients have an increased risk of comorbidities, such as atrial fibrillation (AF) and venous thromboembolism (VTE), which includes pulmonary embolism (PE) and deep-vein thrombosis (DVT). These may require therapeutic anticoagulant therapy (ACT). Limited data are available on the risk of intracranial hemorrhage (ICH) after SRS for patients with BM who are receiving ACT. This bi-institutional analysis aimed to describe the bleeding risk for this patient subgroup.
METHODS
METHODS
Patients with ACT at the time of single-fraction SRS for BM from two institutions were eligible for analysis. The cumulative incidence of ICH with death as a competing event was assessed during follow-up with magnetic resonance imaging or computed tomography.
RESULTS
RESULTS
Forty-one patients with 97 BM were included in the analyses. The median follow-up was 8.2 months (range: 1.7-77.5 months). The median and mean BM volumes were 0.47 and 1.19 cubic centimeters, respectively. The most common reasons for ACT were PE (41%), AF (34%), and DVT (7%). The ACT was mostly performed utilizing phenprocoumon (37%), novel oral anticoagulants (32%), or low-molecular-weight heparin (20%). Nine BM from a group of five patients with ICH after SRS were identified: none of them caused neurological or any other deficits. The 6-, 12-, and 18-month cumulative bleeding incidences per metastasis were 2.1%, 12.4%, and 12.4%, respectively. The metastases with previous bleeding events and those originating from malignant melanomas were found to more frequently demonstrate ICH after SRS (
CONCLUSION
CONCLUSIONS
Patients receiving an ACT and single-fraction SRS for small- to medium-sized BM did not seem to have a clinically relevant risk of ICH. Previous bleeding and metastases originating from a malignant melanoma may favor bleeding events after SRS. Further studies are needed to validate our reported findings.
Identifiants
pubmed: 35158734
pii: cancers14030465
doi: 10.3390/cancers14030465
pmc: PMC8833468
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Stroke. 2006 Jan;37(1):256-62
pubmed: 16339459
Br J Neurosurg. 2009 Aug;23(4):431-6
pubmed: 19637016
J Neurosurg. 1987 Dec;67(6):852-7
pubmed: 3316531
World Neurosurg. 2018 Sep;117:246-248
pubmed: 29936208
Neuro Oncol. 2012 Sep;14 Suppl 4:iv73-80
pubmed: 23095833
Radiother Oncol. 2018 Nov;129(2):364-369
pubmed: 30293644
J Neurooncol. 2015 May;122(3):421-9
pubmed: 25670390
J Neurosurg. 2008 Dec;109 Suppl:99-105
pubmed: 19123895
J Radiosurg SBRT. 2014;3(1):43-50
pubmed: 29296384
AJNR Am J Neuroradiol. 1995 Apr;16(4):693-9
pubmed: 7611024
J Thromb Haemost. 2019 Jan;17(1):72-76
pubmed: 30450803
Radiology. 2004 Jan;230(1):93-9
pubmed: 14645879
Radiology. 1994 Dec;193(3):629-36
pubmed: 7972799
No Shinkei Geka. 1994 Aug;22(8):789-93
pubmed: 8072640
Cancer Treat Res. 2019;179:179-189
pubmed: 31317488
Thromb Haemost. 2017 Jan 26;117(2):219-230
pubmed: 27882374
Blood Adv. 2020 Dec 22;4(24):6291-6297
pubmed: 33351124
Blood Rev. 2019 May;35:59-67
pubmed: 30928168
Acta Neurochir (Wien). 2012 Sep;154(9):1685-90
pubmed: 22821090
Nat Rev Dis Primers. 2019 Jan 17;5(1):5
pubmed: 30655533
Neurooncol Pract. 2016 Jun;3(2):87-96
pubmed: 31386010
Acta Neurochir (Wien). 2019 Jan;161(1):43-48
pubmed: 30328524
Melanoma Res. 2012 Aug;22(4):310-5
pubmed: 22584956
Minim Invasive Neurosurg. 2006 Aug;49(4):251-4
pubmed: 17041840
Oncologist. 2018 Apr;23(4):468-473
pubmed: 29158366
Otol Neurotol. 2007 Feb;28(2):240-4
pubmed: 17159493
Neuro Oncol. 2017 Feb 1;19(2):162-174
pubmed: 28391295
J Clin Oncol. 2020 Feb 10;38(5):496-520
pubmed: 31381464
J Thromb Haemost. 2016 Sep;14(9):1736-40
pubmed: 27306689
Brain Behav. 2020 Jun;10(6):e01638
pubmed: 32314875
J Neurol Neurosurg Psychiatry. 2003 Jul;74(7):908-12
pubmed: 12810777
J Neurol Neurosurg Psychiatry. 2021 Mar 9;:
pubmed: 33687972
J Clin Oncol. 2005 Sep 1;23(25):6207-19
pubmed: 16135488
J Neurooncol. 2012 Jan;106(1):121-5
pubmed: 21706358
PLoS One. 2018 Oct 5;13(10):e0205454
pubmed: 30289944
Curr Oncol Rep. 2012 Feb;14(1):48-54
pubmed: 22012633
Intern Emerg Med. 2008 Sep;3(3):227-31
pubmed: 18320149
Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):279-87
pubmed: 15850934
J Neurooncol. 2021 May;152(3):483-490
pubmed: 33674992
Anticancer Res. 2012 Nov;32(11):4655-62
pubmed: 23155227
J Clin Oncol. 2004 Jul 15;22(14):2865-72
pubmed: 15254054
Can J Neurol Sci. 2009 May;36(3):303-10
pubmed: 19534329
Cancer. 1994 Jan 15;73(2):493-8
pubmed: 8293418
Blood. 2015 Jul 23;126(4):494-9
pubmed: 25987658
Med Oncol. 2018 Mar 1;35(4):43
pubmed: 29497873
J Radiosurg SBRT. 2011;1(2):163-168
pubmed: 29296311
Prog Neurol Surg. 2012;25:201-9
pubmed: 22236681
Intern Emerg Med. 2012 Oct;7(5):431-8
pubmed: 21968511
Int J Stroke. 2011 Jun;6(3):228-40
pubmed: 21557810